PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Profound Medical Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.86−0.15 (-2.50%)
Close on Oct 19, 2026
- Market cap
- $213.01M
- P/E (TTM)
- 4.2
- Dividend yield
- –
Profound Medical Corp. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Recurring - non-capital | $9.73M | $8.24M | $6.81M | – | – | – | – | 60.4% | +18.1% |
| Capital equipment | $6.37M | $2.44M | $393.00K | $4.68M | $3.15M | $4.58M | – | 39.6% | +161.0% |
| Recurring - non-capital | – | – | $393.00K | $2.00M | $3.72M | $2.72M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $12.25M | $7.35M | $5.13M | $3.40M | $2.09M | – | – | 76.1% | +66.6% |
| Canada | $3.08M | $2.44M | $230.00K | $1.49M | $2.08M | $6.49M | $2.43M | 19.1% | +26.3% |
| Germany | $773.00K | $891.00K | $1.84M | $1.80M | $2.71M | $819.00K | $1.75M | 4.8% | -13.2% |
From the segment and revenue-disaggregation notes of Profound Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.